By Turna Ray

University of Maryland researchers have confirmed in a genome-wide association study that the CYP2C19*2 polymorphism plays a "major role" in how patients respond to the anti-clotting drug Plavix (clopidogrel).

The researchers now plan to conduct a prospective, randomized-controlled trial and form a pharmacogenomics consortium specifically focused on validating and discovering new gene-response variants for the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.